What is HC Wainwright’s Estimate for Oculis Q2 Earnings?

Oculis Holding AG (NASDAQ:OCS) – Equities research analysts at HC Wainwright decreased their Q2 2025 EPS estimates for Oculis in a research report issued on Monday, May 12th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.47) per share for the quarter, down from their prior estimate of ($0.41). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($1.69) EPS.

Oculis (NASDAQ:OCS) last announced its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million.

OCS has been the topic of several other reports. Chardan Capital increased their price objective on shares of Oculis from $28.00 to $33.00 and gave the company a “buy” rating in a report on Friday, May 9th. Robert W. Baird increased their price objective on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, March 13th.

Oculis Price Performance

Shares of OCS stock opened at $18.30 on Wednesday. The firm’s 50 day moving average is $17.96 and its 200-day moving average is $18.40. Oculis has a 1 year low of $10.79 and a 1 year high of $23.08. The firm has a market capitalization of $799.01 million, a price-to-earnings ratio of -9.48 and a beta of 0.27. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after purchasing an additional 1,800 shares during the period. Bellevue Group AG bought a new stake in shares of Oculis during the fourth quarter worth $170,000. Bank of America Corp DE increased its position in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after acquiring an additional 10,667 shares in the last quarter. Kestra Private Wealth Services LLC bought a new stake in shares of Oculis during the first quarter worth $234,000. Finally, XTX Topco Ltd bought a new stake in shares of Oculis during the fourth quarter worth $225,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.